0001193125-26-133259
SEC filingSCYNEXIS, Inc. entered into a private placement agreement on March 30, 2026, to raise approximately $40.0 million in gross proceeds, with potential for an additional $52.2 million if warrants are fully exercised, extending its estimated cash runway into mid-2029.
SCYNEXIS has secured a significant capital infusion through a private placement, addressing its near-term funding needs with an estimated $40.0 million in gross proceeds. The financing structure includes immediate equity issuance and warrants that could provide an additional $52.2 million if fully exercised, though this is contingent on obtaining stockholder approval for an increase in authorized shares. The company's disclosure that these funds extend its cash runway into mid-2029 provides investors with visibility into its operational timeline, particularly for its Phase 2 proof-of-concept study of SCY-770 in ADPKD. The warrant terms create a potential future equity overhang, with Common Warrants exercisable at $1.20 per share and containing an acceleration clause tied to the release of Week 48 topline data from the SCY-770 study. The participation of both new and existing institutional investors, along with the CEO's personal investment, signals confidence in the company's direction. The registration rights commitment ensures investors will have liquidity for their shares once the registration statement becomes effective, though the securities currently trade with restrictions as unregistered offerings.